Longevity Health Holdings Inc. (XAGE)

US — Healthcare Sector
Peers:

Automate Your Wheel Strategy on XAGE

With Tiblio's Option Bot, you can configure your own wheel strategy including XAGE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol XAGE
  • Rev/Share 0.0024
  • Book/Share -0.2254
  • PB -11.7111
  • Debt/Equity -0.1356
  • CurrentRatio 0.1626
  • ROIC 1.3589

 

  • MktCap 2650534.0
  • FreeCF/Share -0.2099
  • PFCF -0.6039
  • PE -4.6368
  • Debt/Assets 0.4335
  • DivYield 0
  • ROE 4.1255

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 2
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Longevity Health Holdings, Inc. Announces Successful Fundraising Via ATM Sale
XAGE
Published: May 27, 2025 by: GlobeNewsWire
Sentiment: Neutral

Pittsburgh, PA, May 27, 2025 (GLOBE NEWSWIRE) -- Longevity Health Holdings, Inc. (Nasdaq: XAGE) (“XAGE,” the “Company,” “we” or “our”), a company dedicated to advancing human longevity and healthy aging through regenerative bio-aesthetics, diagnostics, and nutrition, today announced the successful sale of 479,621 shares of its common stock at an average price of $4.08 per share through its at-the-market (ATM) equity offering facility. Gross proceeds from the ATM sales totaled approximately $1.96 million, prior to deducting fees and expenses.

Read More
image for news Longevity Health Holdings, Inc. Announces Successful Fundraising Via ATM Sale

About Longevity Health Holdings Inc. (XAGE)

  • IPO Date 2021-09-23
  • Website https://www.carmellcosmetics.com
  • Industry Biotechnology
  • CEO Mr. Rajiv Sarman Shukla
  • Employees 15

Longevity Health Holdings Inc focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.